{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:45:42Z","timestamp":1792521942862,"version":"4.5.0"},"reference-count":65,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pulmonary Hypertension (PH) is a common manifestation in patients with Systemic Lupus Erythematosus (SLE) and varies from asymptomatic to life-threatening disease. PH can result not only from immune system dysregulation, but also from various conditions, including cardiorespiratory disorders and thromboembolic diseases. Most commonly, SLE-related PH presents with non-specific symptoms, such as progressive dyspnea on exertion, generalized fatigue and weakness and eventually dyspnea at rest. Prompt diagnosis of SLE-related PH and early identification of the underlying pathogenetic mechanisms is demanded in order to introduce targeted therapy to prevent irreversible pulmonary vascular damage. In most cases the management of PH in SLE patients is similar to idiopathic pulmonary arterial hypertension (PAH). Furthermore, specific diagnostic tools like biomarkers or screening protocols, to establish early diagnosis seem to be not available yet. Although, the survival rates for patients with SLE-related PH vary between studies, it is evident that PH presence negatively affects the survival of SLE patients.<\/jats:p>","DOI":"10.3390\/ijms24065085","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T03:11:39Z","timestamp":1678158699000},"page":"5085","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Systemic Lupus Erythematosus and Pulmonary Hypertension"],"prefix":"10.3390","volume":"24","author":[{"given":"Konstantinos","family":"Parperis","sequence":"first","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia CY2024, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-0048","authenticated-orcid":false,"given":"Nikolaos","family":"Velidakis","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia CY2024, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Khattab","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia CY2024, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Gkougkoudi","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia CY2024, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-3488","authenticated-orcid":false,"given":"Nikolaos P. E.","family":"Kadoglou","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia CY2024, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.41632","article-title":"Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries","volume":"73","author":"Izmirly","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/BOR.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: An update","volume":"30","author":"Stojan","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1685537","article-title":"Pulmonary Complications of Systemic Lupus Erythematosus","volume":"40","author":"Hannah","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_6","first-page":"294","article-title":"Pulmonary manifestations in systemic lupus erythematosus: Pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage","volume":"14","year":"2018","journal-title":"Reumatol. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"610257","DOI":"10.3389\/fmed.2020.610257","article-title":"Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus","volume":"7","author":"Amarnani","year":"2021","journal-title":"Front. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1573397113666170704102444","article-title":"Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus","volume":"13","author":"Tselios","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"854941","DOI":"10.1155\/2012\/854941","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus: Current status and future direction","volume":"2012","author":"Dhala","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/rheumatology\/kep203","article-title":"Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus","volume":"48","author":"Prabu","year":"2009","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0034-1371537","article-title":"Pulmonary manifestations of systemic lupus erythematosus","volume":"35","author":"Mittoo","year":"2014","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1017\/S1047951121000688","article-title":"Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus","volume":"31","author":"Lei","year":"2021","journal-title":"Cardiol. Young"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00296-011-1880-4","article-title":"Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus","volume":"32","author":"Lian","year":"2012","journal-title":"Rheumatol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5606\/ArchRheumatol.2019.6780","article-title":"Clinical Features and Risk Factors of Pulmonary Hypertension in Chinese Patients With Systemic Lupus Erythematosus","volume":"34","author":"Chen","year":"2018","journal-title":"Arch. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1378\/chest.10-0227","article-title":"Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases","volume":"140","author":"Luo","year":"2011","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/0961203314527366","article-title":"Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus","volume":"23","author":"Li","year":"2014","journal-title":"Lupus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2761","DOI":"10.1097\/MD.0000000000002761","article-title":"Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OARRR.S123549","article-title":"Systemic lupus erythematosus and pulmonary arterial hypertension: Links, risks, and management strategies","volume":"9","author":"Tselios","year":"2016","journal-title":"Open Access Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"658341","DOI":"10.3389\/fimmu.2021.658341","article-title":"Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Systemic Lupus Erythematosus and Pulmonary Arterial Hypertension: Evidence From Transcriptome Data","volume":"12","author":"Yao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/1744666X.2021.1825940","article-title":"Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: Current recommendations and recent advances","volume":"16","author":"Kato","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/rheumatology\/kev097","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: An observational study","volume":"54","author":"Kommireddy","year":"2015","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/art.23303","article-title":"Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases","volume":"58","author":"Jais","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/0961203319860192","article-title":"Complement alternative pathway activation associated with pulmonary hypertension in lupus nephritis patients","volume":"28","author":"Li","year":"2019","journal-title":"Lupus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1183\/09059180.00003811","article-title":"Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus","volume":"20","author":"Johnson","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajpath.2011.03.040","article-title":"Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment","volume":"179","author":"Jonigk","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2003957","DOI":"10.1183\/13993003.03957-2020","article-title":"Endothelial cells in the pathogenesis of pulmonary arterial hypertension","volume":"58","author":"Evans","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1191\/0961203304lu509oa","article-title":"Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus","volume":"13","author":"Celis","year":"2004","journal-title":"Lupus"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0049-0172(84)90015-5","article-title":"Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus","volume":"13","author":"Quismorio","year":"1984","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCRESAHA.114.302221","article-title":"Evidence for the involvement of type I interferon in pulmonary arterial hypertension","volume":"114","author":"George","year":"2014","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.12669\/pjms.35.1.405","article-title":"Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus","volume":"35","author":"Asif","year":"2019","journal-title":"Pak. J. Med. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0961203307087188","article-title":"An update in pulmonary hypertension in systemic lupus erythematosus\u2014Do we need to know about it?","volume":"17","author":"Pope","year":"2008","journal-title":"Lupus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","first-page":"343","article-title":"Pulmonary fibrosis, part I: Epidemiology, pathogenesis, and diagnosis","volume":"11","author":"Meyer","year":"2017","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ccm.2020.11.014","article-title":"Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension","volume":"42","author":"Lang","year":"2021","journal-title":"Clin. Chest. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","article-title":"Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imaging","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/1756-185X.12262","article-title":"High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension","volume":"18","author":"Kim","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/0961203315600539","article-title":"Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: A seven-year follow-up study","volume":"25","author":"Sandoval","year":"2016","journal-title":"Lupus"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3904\/kjim.2015.30.2.232","article-title":"Pulmonary hypertension in systemic lupus erythematosus: An independent predictor of patient survival","volume":"30","author":"Min","year":"2015","journal-title":"Korean J. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/art.39212","article-title":"Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension","volume":"67","author":"Guo","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00296-009-1255-2","article-title":"Pulmonary hypertension in systemic lupus erythematosus: Relationship with antiphospholipid antibodies and severe disease outcome","volume":"31","author":"Cefle","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_43","first-page":"75","article-title":"Immunological studies in \u2018primary\u2019 idiopathic pulmonary hypertension","volume":"7","author":"Asherson","year":"1984","journal-title":"Eur. J. Rheumatol. Inflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2017.04.003","article-title":"Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis","volume":"16","author":"Zuily","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/art.41740","article-title":"Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study","volume":"73","author":"Qu","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4137\/CMAMD.S7667","article-title":"Asymptomatic pulmonary hypertension in systemic lupus erythematosus","volume":"4","author":"Kamel","year":"2011","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0961203311429815","article-title":"Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension","volume":"21","author":"Chow","year":"2012","journal-title":"Lupus"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/1529-0131(200102)44:2<376::AID-ANR56>3.0.CO;2-2","article-title":"Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus","volume":"44","author":"Gussin","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1038\/s41598-017-08099-3","article-title":"Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE","volume":"7","author":"Hu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e000356","DOI":"10.1136\/lupus-2019-000356","article-title":"Autoantibody clustering of lupus-associated pulmonary hypertension","volume":"6","author":"Mizus","year":"2019","journal-title":"Lupus Sci. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1051\/bmdcn\/2018080316","article-title":"Evaluation of serum uric acid level in systemic lupus erythematosus patients with normal and high pulmonary arterial hypertension","volume":"8","author":"Aghdashi","year":"2018","journal-title":"Biomedicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1759720X211040696","DOI":"10.1177\/1759720X211040696","article-title":"Diagnosis and management of lung involvement in systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome: A literature review","volume":"13","author":"Depascale","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e004757","DOI":"10.1161\/CIRCOUTCOMES.118.004757","article-title":"Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?","volume":"11","author":"Khan","year":"2018","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","article-title":"Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension","volume":"31","author":"Montani","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: Post hoc analysis","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","article-title":"Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2","volume":"76","author":"Humbert","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.117.1.14","article-title":"Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus","volume":"117","author":"Robbins","year":"2000","journal-title":"Chest"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2017.08.014","article-title":"Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry","volume":"153","author":"Hachulla","year":"2018","journal-title":"Chest"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/art.39432","article-title":"Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension","volume":"68","author":"Sobanski","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1183\/09031936.00182813","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients","volume":"44","author":"Hao","year":"2014","journal-title":"Eur. Respir. J."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5085\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:49:41Z","timestamp":1760122181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065085"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065085","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}